Asset Details
Do you wish to reserve the book?
Long-term trends in use of and expenditures for cardiovascular medications in Canada
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-term trends in use of and expenditures for cardiovascular medications in Canada
Do you wish to request the book?
Long-term trends in use of and expenditures for cardiovascular medications in Canada
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-term trends in use of and expenditures for cardiovascular medications in Canada
2009
Overview
Medication expenditures have become the fastest growing sector of costs within the Canadian health care system. Evaluation of the use of cardiovascular medications is important to determine the magnitude of the growth, to identify which medications dominate the landscape and to detect interprovincial differences in utilization. We describe long-term trends in the use of and expenditures for cardiovascular medications in Canada, by drug class and by province.
For these analyses, we used volume and expenditure data related to prescriptions for cardiovascular medications obtained from IMS Health Canada's CompuScript Audit® database for the period 1996–2006. Here, we describe national and provincial patterns of utilization and expenditures for specified classes of cardiovascular medications.
The use of cardiovascular medications increased sharply in Canada during the study period, with related costs rising by over 200% during this period to surpass $5 billion in 2006. Changes in population demographics, risk factors and inflation appeared to account for about two-thirds of the observed growth in expenditures. Use of newer medication classes (statins, angiotensin-receptor blockers, angiotensin-converting-enzyme inhibitors), for which patented brand name medications predominate, accounted for almost one-third of the cost increases. Interprovincial differences in total expenditures for cardiovascular drugs portrayed a descending gradient from east to west, with greatest variability for the newer drug classes.
Prescriptions and expenditures for cardiovascular medications in Canada escalated over the study period. Projected increases may reach potentially unsustainable levels. Greater emphasis on the use of cost-effective medications is required to limit further increases. Factors influencing interprovincial differences warrant further study.
Une version française de ce résumé est disponible à l'adresse www.cmaj.ca/cgi/content/full/cmaj.081913/DC1
CMAJ 2009;181(1–2):E19-E28
Publisher
Elsevier Inc,CMA Impact Inc,CMA Impact, Inc,Canadian Medical Association
